The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
9 Primary · 7 Secondary · Reporting Duration: Baseline up to 36 months
Experimental Treatment
1400 Total Participants · 1 Treatment Group
Primary Treatment: Eplontersen · No Placebo Group · Phase 3
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: